Shannon Kasperbauer, MD

Associate Professor of Medicine
Department of Medicine
Division of Mycobacterial & Respiratory Infections
National Jewish
Denver, Colorado

Video

What are the characteristics and/or risk factors that predispose patients to MAC lung infection? And what species are particularly relevant and widespread causative pathogens in NTM lung disease?

Shannon Kasperbauer, MD

Video

What is it about the non-specific symptomatology that characterizes the broad clinical spectrum of MAC lung disease that creates diagnostic challenges for the clinician?

Shannon Kasperbauer, MD

Video

What are the most effective methods for sputum induction and microbiologic sampling? And, in your experience, in what percentage of cases is a bronchoscopy or lung biopsy necessary to achieve microbiologic confirmation of MAC lung disease?

Shannon Kasperbauer, MD

Video

What are the relevance, role, and clinical importance of obtaining and documenting in vitro culture drug sensitivity testing to antibiotics considered for treatment of MAC lung disease?

Shannon Kasperbauer, MD

Video

What clinical findings absolutely mandate antibiotic treatment for individuals with culture-positive MAC lung disease? What is the gray area?

Shannon Kasperbauer, MD

Video

What are the predictors of progressive MAC lung disease and what are the guideline-based (ATS/IDSA/BTS) recommendations for antibiotic treatment in these high-risk patients?

Shannon Kasperbauer, MD

Video

Why is continuous airway clearance an important pillar of therapy for patients with MAC lung disease?

Shannon Kasperbauer, MD

Video

What is the role of molecular diagnostics and speciating NTM organisms as part of the microbiological characterization for MAC lung infection?

Shannon Kasperbauer, MD

Video

When intensification of therapy with amikacin is being considered, or has been implemented in patients, how do you differentiate between and/or decide to initiate therapy with the IV vs. amikacin liposome inhalation suspension formulation?

Shannon Kasperbauer, MD

$What were the conclusions of the NTM-NET Consensus Guidelines as far as the definition of treatment refractoriness in MAC lung disease, and what’s your assessment of these recommendations?$ Video

What were the conclusions of the NTM-NET Consensus Guidelines as far as the definition of treatment refractoriness in MAC lung disease, and what’s your assessment of these recommendations?

Shannon Kasperbauer, MD

$Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?$ Video

Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?

Shannon Kasperbauer, MD

Video

Can you share a specific case that exemplifies at least one clinical phenotype with MAC lung disease that is appropriately managed with amikacin liposome inhaled suspension?

Shannon Kasperbauer, MD

Video

What have you learned about the role of and approach to using amikacin liposome aerosol suspension from the previous—and similar other—cases of MAC lung disease that you have managed?

Shannon Kasperbauer, MD

Video

Can you summarize the current evidence for amikacin liposome inhaled suspension, the patients in which it is appropriately deployed, and what supportive and educational measures improve toleration, adherence and durability of long-term treatment?

Shannon Kasperbauer, MD